Health and Healthcare

Celgene : CELG

All CELG Articles

433 Articles

Lee Jackson | Apr 26, 2016 at 10:05 AM EDT

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

Typically each year, the first quarter is the slowest for biotech stocks. SunTrust Robinson Humphrey has four stocks rated Buy…

Chris Lange | Apr 12, 2016 at 9:55 AM EDT

Short Sellers Run for Cover From Major Biotechs

The March 31 short interest data have been compared with the previous report, and short interest decreased across the board…

Lee Jackson | Apr 12, 2016 at 8:25 AM EDT

Top Biotech Picks Highlight Jefferies Growth Stocks to Buy

A new Jefferies research report highlights their top growth picks for this week, and the list is dominated by top…

Lee Jackson | Apr 7, 2016 at 10:10 AM EDT

3 Hot Growth Stocks With Upside Potential That May Not Be Appreciated by Wall Street

Sometimes after a stock has a good run, the analysts on Wall Street start to get a little gun-shy, especially…

Chris Lange | Apr 6, 2016 at 10:05 AM EDT

5 Biotechs With the Most Upside This Earnings Cycle

Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help…

Jon C. Ogg | Mar 23, 2016 at 8:45 AM EDT

The Next Mega-Caps: 7 Stocks Likely to Be Worth $100 Billion Soon

24/7 Wall St. has identified seven companies that could easily reach the $100 billion mark to become the next mega-cap…

Chris Lange | Mar 10, 2016 at 8:05 AM EST

Short Sellers Back Off of Major Biotechs

The February 29 short interest data have been compared with the previous report, and short interest decreased across the board…

Chris Lange | Mar 6, 2016 at 10:40 AM EST

3 Top Biopharma Movers of the Past Week

Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.

Jon C. Ogg | Feb 25, 2016 at 5:15 PM EST

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four…

Chris Lange | Feb 25, 2016 at 8:46 AM EST

Short Interest Rises Across the Board in Major Biotechs

The February 12 short interest data have been compared with the previous report, and short interest increased across the board…

Chris Lange | Feb 10, 2016 at 8:40 AM EST

Major Biotech Short Interest Continues to Be Mixed

The January 29 short interest data have been compared with the previous report, and short interest was mixed in most…

Lee Jackson | Feb 1, 2016 at 9:50 AM EST

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

A recent Jefferies research note indicates that the multiples for the four largest biotechs have dipped below that of the…

Chris Lange | Jan 28, 2016 at 12:05 PM EST

Celgene Earnings, Guidance Fail to Live Up to Investor Expectations

Celgene reported mixed fourth-quarter financial results before the markets opened on Thursday.

Lee Jackson | Jan 28, 2016 at 10:10 AM EST

Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now

Jefferies has four top biotech picks for 2016 that all have substantial upside and may provide investors with solid alpha…

Chris Lange | Jan 28, 2016 at 8:35 AM EST

Short Sellers Increase Bets in Major Biotechs

Short interest increased in most of these selected biotech stocks for the most recent settlement date.

1 … 12 13 14 15 16 … 29

Celgene : CELG

All CELG Articles

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

Short Sellers Run for Cover From Major Biotechs

Top Biotech Picks Highlight Jefferies Growth Stocks to Buy

3 Hot Growth Stocks With Upside Potential That May Not Be Appreciated by Wall Street

5 Biotechs With the Most Upside This Earnings Cycle

The Next Mega-Caps: 7 Stocks Likely to Be Worth $100 Billion Soon

Short Sellers Back Off of Major Biotechs

3 Top Biopharma Movers of the Past Week

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Major Biotech Short Interest Continues to Be Mixed

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

Celgene Earnings, Guidance Fail to Live Up to Investor Expectations

Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now

Short Sellers Increase Bets in Major Biotechs

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Celgene : CELG

All CELG Articles

4 Biotechs That Will Escape Weak Seasonal Trends for the Sector

Short Sellers Run for Cover From Major Biotechs

Top Biotech Picks Highlight Jefferies Growth Stocks to Buy

3 Hot Growth Stocks With Upside Potential That May Not Be Appreciated by Wall Street

5 Biotechs With the Most Upside This Earnings Cycle

The Next Mega-Caps: 7 Stocks Likely to Be Worth $100 Billion Soon

Short Sellers Back Off of Major Biotechs

3 Top Biopharma Movers of the Past Week

Why Citi Sees Huge Upside in 4 Top Biotechs Now

Short Interest Rises Across the Board in Major Biotechs

Major Biotech Short Interest Continues to Be Mixed

The 4 Largest Biotech Stocks Are Cheaper Than S&P 500

Celgene Earnings, Guidance Fail to Live Up to Investor Expectations

Biotech Is the Cheapest Since 2011: 4 Top Stocks to Buy Now

Short Sellers Increase Bets in Major Biotechs

This High-Yield Emerging Funds ETF Offers International Diversification

A 71-Year-Old’s $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy’s 25% Savings Rule Actually Starts at 15%

Featured Reads

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

Why The Money Guy's 25% Savings Rule Actually Starts at 15%